StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.51−0.30 (-1.08%)

Close on Nov 18, 2026Market cap $1.42BP/E –Yield 0.00%

Immunocore revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Immunocore's revenue for the twelve months ending Jun 30, 2026 was $430.78M, up 21.0% year over year. For fiscal 2025 it was $400.02M, up 29.0% from the year before. The highest annual figure on record is $400.02M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$400.02M+29.0%
FY2024Dec 31, 2024$310.20M+24.4%
FY2023Dec 31, 2023$249.43M+43.1%
FY2022Dec 31, 2022$174.36M+377.9%
FY2021Dec 31, 2021$36.48M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$115.93M+18.3%
Q1 FY2026Mar 31, 2026$106.68M+13.6%
Q4 FY2025Dec 31, 2025$104.48M+24.3%
Q3 FY2025Sep 30, 2025$103.69M+29.2%
Q2 FY2025Jun 30, 2025$97.96M+29.9%
Q1 FY2025Mar 31, 2025$93.88M+33.2%
Q4 FY2024Dec 31, 2024$84.05M+19.8%
Q3 FY2024Sep 30, 2024$80.25M+23.7%
Q2 FY2024Jun 30, 2024$75.40M+26.2%
Q1 FY2024Mar 31, 2024$70.50M+29.0%
Q4 FY2023Dec 31, 2023$70.16M–
Q3 FY2023Sep 30, 2023$64.85M–
Q2 FY2023Jun 30, 2023$59.76M–
Q1 FY2023Mar 31, 2023$54.66M–

More Immunocore figures

See a number that looks wrong?